Physician profile
Rene Torres
NPI 1275943169
$2,792.35
in general payments reported to CMS, 2019-2025
26 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $629 · 2022: $564 · 2023: $646 · 2024: $500 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,015.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $373.53 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $321.51 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $234.01 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $126.23 | 2021-2025 | |
| Insulet Corporation | $125.09 | 2021-2025 | Omnipod |
| Pfizer INC. | $93.61 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $69.40 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $66.67 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $41.26 | 2022-2024 | Eliquis |
| Genentech USA, INC. | $38.82 | 2021 | |
| Amgen INC. | $30.70 | 2024-2025 | Krystexxa, Prolia, Evenity |
| Paratek Pharmaceuticals, INC. | $28.83 | 2022 | |
| Hologic Sales and Service, LLC | $28.32 | 2025 | Aptima |
| Dexcom, INC. | $27.30 | 2021-2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.92 | 2025 | Caplyta |
| Verona Pharma, INC. | $19.10 | 2025 | Ohtuvayre |
| Exact Sciences Corporation | $19.10 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $18.33 | 2021 | |
| Phadia US INC. | $17.77 | 2024 | Immunocap |
| Xeris Pharmaceuticals, INC. | $16.13 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $15.76 | 2023 | |
| Astellas Pharma US INC | $15.02 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.81 | 2024 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $13.66 | 2025 | |
| Phathom Pharmaceuticals, INC. | $2.09 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.